Breast Cancer Clinical Trial
Official title:
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection in Patients With Locally Advanced or Metastatic Solid Tumours
This is a first-in-human Phase 1/2, non-randomized, multi-centre, open-label clinical study designed to investigate safety, tolerability, PK, and preliminary anti-tumour activity of [225Ac]-FPI-1434 (radioimmuno-therapeutic agent) in patients with solid tumours that demonstrate uptake of [111In]-FPI-1547 (radioimmuno-imaging agent), and to establish the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of repeat doses of [225Ac]-FPI-1434 Injection in patients with solid tumours that demonstrate uptake of [111In]-FPI-1547 (radioimmuno-imaging agent).
Status | Recruiting |
Enrollment | 253 |
Est. completion date | June 2026 |
Est. primary completion date | June 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Pathologically documented, definitively diagnosed, advanced solid tumour that is refractory to all standard treatment, for which no standard treatment is available, or it is contraindicated, or the patient refuses standard therapy. 2. Measurable or evaluable disease in accordance with RECIST 1.1. 3. Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1. 4. Life expectancy of greater than 3 months as judged by the treating physician. 5. Available tumour tissue (either archival or fresh biopsy) for IGF-1R immunohistochemistry. Submission of the tissue is not required prior to enrollment. 6. Adequate heart, kidney, and liver function 7. Adequate bone marrow reserves 8. Ability to understand and the willingness to sign a written informed consent document. Phase 2 Specific 9. Histologically and/or cytologically documented diagnosis of locally advanced, inoperable, metastatic, or recurrent solid tumour types: endometrial, cervical, ovarian, TNBC, HER 2-negative breast, HNSCC, ACC, or uveal melanoma. 10. Have measurable disease per RECIST 1.1 Failure to respond to standard systemic therapy, or for whom standard or curative systemic therapy does not exist or is not tolerable. Imaging Eligibility 11. Prior to the initial [225Ac]-FPI-1434 cycle: Sufficient target expression in at least 1 lesion following [111In]-FPI-1547 and SPECT imaging. Exclusion Criteria: 1. Systemic therapeutic radiopharmaceutical within 6 months prior to enrollment into this study. 2. Contraindications to or inability to perform the required imaging procedures in this study (e.g., inability to lay flat during scan time) 3. Uncontrolled brain metastasis, including but not limited to the need for treatment with steroids, surgery or radiation therapy. 4. Anticancer therapy (including investigational agents) or external beam radiation therapy within 14 days of the dosing of [111In]-FPI-1547 5. Has known additional malignancy that is progressing or has required active treatment within the past 3 years. Patients with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ (e.g., breast cancer, cervical cancer, prostate) that have undergone potentially curative therapy are not excluded. 6. Residual CTCAE = Grade 2 side effects of prior therapy, with the exception of residual grade 2 alopecia. 7. Prior organ transplantation, including stem cell transplantation. 8. Any prior treatment with nitrosoureas or actinomycin-D. 9. Clinically relevant levels of protein in the urine 10. Known or suspected allergies or contraindications to the Investigational Products or any component of the investigational drug formulation. 11. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, diabetes, or psychiatric illness/social situations that would limit compliance with study requirements. 12. Received > 20 Gy prior radiation to large areas of the bone marrow |
Country | Name | City | State |
---|---|---|---|
Australia | Royal Adelaide Hospital | Adelaide | South Australia |
Australia | Austin Hospital | Heidelberg | Victoria |
Canada | Juravinski Cancer Center - Hamilton Health | Hamilton | Ontario |
Canada | Centre Hospitalier De I'Universite de Montreal | Montréal | Quebec |
Canada | Quebec University Hospital- Laval | Québec City | Quebec |
Canada | Princess Margaret Cancer Centre | Toronto | Ontario |
United States | Dana-Farber Cancer Institute | Boston | Massachusetts |
United States | Roswell Park Comprehensive Cancer Center | Buffalo | New York |
United States | City of Hope | Duarte | California |
United States | University of Texas MD Anderson Cancer Center | Houston | Texas |
United States | Masonic Cancer Center, University of Minnesota | Minneapolis | Minnesota |
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
United States | Hospital of the University of Pennsylvania | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Fusion Pharmaceuticals Inc. |
United States, Australia, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dose Escalation: Incidence of adverse events (AEs). | Phase 1 | Approximately one year post final [225Ac]-FPI-1434 Injection. | |
Primary | Single-Dose Escalation: Incidence of dose limiting toxicities (DLTs). | Phase 1 | 8 weeks. | |
Primary | Multi-Dose Escalation: Incidence of DLTs. | Phase 1 | 6 weeks. | |
Primary | Dose Escalation: Incidence of clinically significant clinical laboratory abnormalities. | Phase 1 | Approximately one year post final [225Ac]-FPI-1434 Injection. | |
Primary | Dose Escalation: Changes in electrocardiogram (ECG) parameters (PR, QRS, QT, and QTc intervals). | Phase 1 | 4 weeks post final [225Ac]-FPI-1434 Injection. | |
Primary | Cold Antibody Sub-Study: Changes in uptake of [111In]-FPI-1547 Injection following FPI-1175 Infusion in selected regions of interest on SPECT/CT images. | Phase 1 | Within two weeks of the first [111In]-FPI-1547 Injection. | |
Primary | Cold Antibody Sub-Study: Changes in radiation dose estimates for selected tissues, organs and whole body both for [111In]-FPI-1547 and [225Ac]-FPI-1434 Injection at various dose levels following FPI-1175 Infusion. | Phase 1 | Within two weeks of the first [111In]-FPI-1547 Injection. | |
Primary | Evaluate anti-tumour activity of [225Ac]-FPI-1434 regimen | Phase 2 | Approximately one year post final [225Ac]-FPI-1434 injection. | |
Primary | Objective response rate (ORR) RECIST v1.1. | Phase 2 | Approximately one year post final [225Ac]-FPI-1434 Injection. | |
Secondary | Dose Escalation and Cold Antibody Sub-Study: Tumour uptake of [111In]-FPI-1547 in selected regions of interest on SPECT/CT images. | Phase 1 and 2 | Dose Escalation: Within one week of the [111In]-FPI-1547 Injection. Cold-Antibody Sub-Study: Within two weeks of the first [111In]-FPI-1547 Injection. | |
Secondary | Dose Escalation: Radiation doses for selected organs and whole body both for [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection. | Phase 1 and 2 | Within one week of the [111In]-FPI-1547 Injection. | |
Secondary | Dose Escalation and Cold-Antibody Sub-Study: Changes in radiation absorbed doses for tumour lesions for [225Ac]-FPI-1434. | Phase 1 and 2 | Dose Escalation: Within one week of the [111In]-FPI-1547 Injection. Cold-Antibody Sub-Study: Within two weeks of the first [111In]-FPI-1547 Injection. | |
Secondary | Dose Escalation and Cold-Antibody Sub-Study: Clearance for radioactivity and for the targeting antibody. | Phase 1 and 2 | 4 weeks post final [225Ac]-FPI-1434 Injection. | |
Secondary | Dose Escalation and Cold-Antibody Sub-Study: Area under the curve (AUC) for radioactivity and for the targeting antibody. | Phase 1 and 2 | 4 weeks post final [225Ac]-FPI-1434 Injection. | |
Secondary | Dose Escalation and Cold-Antibody Sub-Study: Cmax for radioactivity and for the targeting antibody. | Phase 1 and 2 | 4 weeks post final [225Ac]-FPI-1434 Injection. | |
Secondary | Dose Escalation and Cold-Antibody Sub-Study: Half-life for radioactivity and for the targeting antibody. | Phase 1 and 2 | 4 weeks post final [225Ac]-FPI-1434 Injection. | |
Secondary | Dose Escalation and Cold-Antibody Sub-Study: Objective response rate (ORR) (sum of complete and partial response) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or Prostate Cancer Working Group 3 (PCWG3) guidelines. | Phase 1 | Approximately one year post final [225Ac]-FPI-1434 Injection. | |
Secondary | Dose Escalation: Changes in the corrected QT (QTc) interval in milliseconds after [225Ac]-FPI-1434 treatment, compared to baseline. | Phase 1 and 2 | Approximately 24 hours from the time of [225Ac]-FPI-1434 Injection administration. | |
Secondary | Dose Escalation and Cold-Antibody Sub-Study: Changes in human growth hormone (hGh) following [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection. | Phase 1 and 2 | 4 weeks post final [225Ac]-FPI-1434 Injection. | |
Secondary | Dose Escalation and Cold-Antibody Sub-Study: Changes in insulin-like growth factor 1 (IGF-1) following [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection. | Phase 1 and 2 | 4 weeks post final [225Ac]-FPI-1434 Injection. | |
Secondary | Dose Escalation and Cold-Antibody Sub-Study: Changes in insulin-like growth factor binding protein 3 (IGFBP-3) following [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection. | Phase 1 and 2 | 4 weeks post final [225Ac]-FPI-1434 Injection. | |
Secondary | Cold Antibody Sub-Study: Incidence of AEs. | Phase 1 and 2 | Approximately one year post final [225Ac]-FPI-1434 Injection. | |
Secondary | Cold Antibody Sub-Study: Incidence of clinically significant clinical laboratory abnormalities. | Phase 1 and 2 | Approximately one year post final [225Ac]-FPI-1434 Injection. | |
Secondary | Cold Antibody Sub-Study: Changes in ECG parameters (PR, QRS, QT, and QTc intervals). | Phase 1 and 2 | 4 weeks post final [225Ac]-FPI-1434 Injection. | |
Secondary | Dose Escalation and Cold-Antibody Sub-Study: Time to response (TTR). | Phase 1 and 2 | Approximately one year post final [225Ac]-FPI-1434 Injection. | |
Secondary | Dose Escalation and Cold-Antibody Sub-Study: Duration of response (DoR). | Phase 1 and 2 | Approximately one year post final [225Ac]-FPI-1434 Injection. | |
Secondary | Dose Escalation and Cold-Antibody Sub-Study: Progression free survival (PFS). | Phase 1 and 2 | Approximately one year post final [225Ac]-FPI-1434 Injection. | |
Secondary | Dose Escalation and Cold-Antibody Sub-Study: Time to Progression (TTP). | Phase 1 and 2 | Approximately one year post final [225Ac]-FPI-1434 Injection. | |
Secondary | Dose Escalation and Cold-Antibody Sub-Study: Disease control rate (DCR). | Phase 1 and 2 | Approximately one year post final [225Ac]-FPI-1434 Injection. | |
Secondary | Dose Escalation and Cold-Antibody Sub-Study: Overall survival (OS). | Phase 1 and 2 | Approximately one year post final [225Ac]-FPI-1434 Injection. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |